2025 Clinical Outcome Assessment Program Annual Meeting Recap

C-Path Clinical Outcome Assessment (COA) Program recently held its Annual Meeting in Rockville, MD. Roughly 300 attendees gathered for two days of sessions and discussions on the methodologies and strategies that will advance drug development and regulatory approaches in clinical outcome assessments across various therapeutic areas.

Be sure to check back in soon for posted materials from the meeting. You can view a detailed recap of the key highlights from the meeting below:

Day 1 Highlights:

- **FDA Updates:** Representatives from the U.S. Food and Drug Administration (FDA) provided insights into the COA Program and other initiatives, emphasizing the integration of patient experience data in regulatory decision-making.
- **Leveraging Digital Health Technologies:** Discussions centered on utilizing digital health tools and partnerships to measure clinically meaningful outcomes, highlighting the role of digital technologies in

enhancing data collection and analysis.

- **eCOA and DHTs in Oncology:** Sessions explored the application of Electronic Clinical Outcome Assessments and Digital Health Technologies in oncology, focusing on their potential to transform data collection and patient monitoring in cancer trials.

- **Clinical Outcome Assessments in Trial Design:** The meeting addressed the use of COAs in trial entry, stratification, and endpoints, discussing evidence and implications to ensure assessments are fit for their intended purposes.

- **Regulatory Pathways for Using Patient Experience Data Pre-and-post-approval:** This session explored how patient experience data (PED) can support product development, labeling claims, and post-marketing surveillance. It emphasized multi-stakeholder collaboration to enhance the utility of PED across the product lifecycle.

Day 2 Highlights:

- **Updates from the Electronic Clinical Outcome Assessment (eCOA) Consortium**: This session highlighted recent advancements and collaborative projects from within eCOA. Key themes included optimizing eCOA implementation in clinical trials, ensuring data integrity, and developing best practices for integrating digital tools. The session also addressed innovations in sensor-based measures and algorithm validation to enhance clinical trial efficiency.

- **Challenges in Rare Disease Populations:** Sessions delved into the unique challenges of conducting COA research in rare pediatric populations, sharing lessons learned and strategies for effective assessment.

- **Future of Patient-Reported Outcomes (PROs):** A forward-looking discussion on optimizing patient-reported outcome data in healthcare decision-making, incorporating multi-stakeholder perspectives to enhance the relevance and impact of PROs.

- **eCOA Collaborations and Updates:** The meeting concluded with updates on collaborative projects leveraging sensor-based measurements and discussions on assessing algorithms for deriving interpretable metrics from raw sensor data.

Overall, the meeting underscored the importance of integrating innovative technologies, addressing unique patient populations' needs, and optimizing patient-reported data to enhance the effectiveness and precision of clinical trials and regulatory processes.


CRITICAL PATH INSTITUTE
20 YEARS OF IMPACT